Kairos Pharma, Ltd. (KAPA)vsModerna Inc (MRNA)
KAPA
Kairos Pharma, Ltd.
$1.73
-4.42%
HEALTHCARE · Cap: $6.26M
MRNA
Moderna Inc
$154.04
-2.55%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
KAPA leads profitability with a 0.0% profit margin vs -141.4%. KAPA earns a higher WallStSmart Score of 23/100 (F).
KAPA
Avoid23
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KAPA.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$154.04
$19.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 9.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : KAPA
The strongest argument for KAPA centers on Price/Book, Altman Z-Score.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : KAPA
The primary concerns for KAPA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
KAPA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
KAPA generates stronger free cash flow (-1M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
KAPA scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kairos Pharma, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. The company is headquartered in Los Angeles, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?